RET and non-small cell lung carcinoma: In particular, regarding lung cancer, Nelson-Taylor et al. demonstrated that ponatinib has potent antiproliferative activity in RET fusion-positive LC-2/ad cells of NSCLC and inhibits phosphorylation of the RET fusion proteins, accompanied by a decreased phosphorylation of AKT and ERK1/2.